TG Ther­a­peu­tics signs $645M deal to kick-start in­ter­na­tion­al launch of MS an­ti­body 

TG Ther­a­peu­tics is look­ing to ex­pand ac­cess to its CD20 an­ti­body Briumvi out­side North Amer­i­ca and has an­nounced a part­ner­ship with the Eu­ro­pean phar­ma com­pa­ny Neu­rax­pharm.

The deal is for $140 mil­lion in cash up­front, plus an­oth­er $12.5 mil­lion once the drug, ap­proved in the US and EU for adults with re­laps­ing forms of mul­ti­ple scle­ro­sis, is launched in the first EU mem­ber coun­try, ac­cord­ing to a press re­lease Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER